E20.1 Pseudohypoparathyroidism

Name of the Condition

• Pseudohypoparathyroidism (ICD-10 Code: E20.1)

Summary

Pseudohypoparathyroidism is a rare genetic disorder characterized by resistance to parathyroid hormone (PTH), leading to low calcium levels (hypocalcemia) and high phosphate levels (hyperphosphatemia). Unlike hypoparathyroidism, where PTH production is insufficient, the parathyroid glands in pseudohypoparathyroidism produce adequate or elevated PTH, but the body’s tissues do not respond to it. This condition can affect multiple systems, including the skeletal, nervous, and renal systems, with symptoms ranging from mild to severe.

Causes

Pseudohypoparathyroidism is caused by genetic mutations that disrupt the signaling pathway of PTH. The most common mutations affect the GNAS gene, which is involved in hormone receptor function. These mutations impair the body’s ability to respond to PTH, even when the hormone is present in normal or elevated levels. The condition is typically inherited in an autosomal dominant pattern, though sporadic cases can occur.

Risk Factors

• Family history of pseudohypoparathyroidism or related genetic disorders.
• Genetic mutations in the GNAS gene or other associated genes.
• Certain racial or ethnic backgrounds with higher prevalence of specific mutations.

Symptoms

• Muscle cramps, spasms, or twitching (tetany).
• Numbness or tingling in the fingers, toes, or around the mouth.
• Fatigue, weakness, or irritability.
• Seizures (in severe cases).
• Short stature or abnormal bone development (e.g., short fourth and fifth metacarpals).
• Round face, short neck, or other subtle dysmorphic features.

Diagnosis

Diagnosis involves measuring blood levels of calcium, phosphate, and PTH. In pseudohypoparathyroidism, PTH levels are typically elevated or inappropriately normal despite low calcium, indicating resistance. Additional tests may include genetic testing to identify mutations in the GNAS gene or related pathways. Urinary cAMP or phosphorus excretion tests can also help confirm PTH resistance.

Treatment Options

Treatment focuses on managing hypocalcemia and hyperphosphatemia. Oral calcium supplements and active vitamin D analogs (e.g., calcitriol) are commonly used to raise calcium levels. Phosphate binders may be prescribed to reduce phosphate absorption. Regular monitoring of calcium, phosphate, and PTH levels is essential to adjust therapy. In some cases, addressing underlying genetic factors or associated conditions may be part of the management plan.

Prognosis and Follow-Up

With proper treatment, many individuals with pseudohypoparathyroidism can manage symptoms and maintain a good quality of life. However, long-term complications, such as kidney stones or bone abnormalities, may occur if calcium and phosphate levels are not well-controlled. Regular follow-up with an endocrinologist is recommended to monitor hormone levels, adjust medications, and address any emerging complications.

Complications

• Chronic hypocalcemia leading to cataracts or dental abnormalities.
• Kidney stones or nephrocalcinosis due to prolonged hyperphosphatemia.
• Neurological issues, such as seizures or cognitive impairment, if untreated.
• Skeletal deformities or growth delays in children.

Lifestyle & Prevention

• Ensure adequate calcium and vitamin D intake through diet or supplements as directed.
• Avoid excessive phosphate intake (e.g., from processed foods or sodas).
• Maintain regular physical activity to support bone health.
• Attend all scheduled medical appointments for monitoring and adjustments to treatment.

When to Seek Professional Help

Seek immediate medical attention if you experience severe symptoms like muscle spasms, seizures, or difficulty breathing, as these may indicate acute hypocalcemia. Contact your healthcare provider if symptoms worsen or new issues arise, such as persistent fatigue, bone pain, or changes in urination.

Tips for Medical Coders

When coding for pseudohypoparathyroidism (E20.1), ensure documentation supports the diagnosis, including lab results showing elevated PTH with low calcium and genetic testing if available. Differentiate from other forms of hypoparathyroidism by confirming PTH resistance. Verify that the code aligns with the clinical presentation and any associated conditions, such as Albright hereditary osteodystrophy, which may be documented separately.